AIMS: The aim of this study was to evaluate the effectiveness of titanium-nitride-oxide (TITANOX)-coated stent and paclitaxel-eluting stent (PES) in patients presenting with acute myocardial infarction (MI). METHODS AND RESULTS: A total of 425 patients presenting with acute non-ST-elevation MI or ST-elevation MI were randomly assigned to receive TITANOX-coated stent or PES. The primary end point was a composite of MI, target lesion revascularisation (TLR) or death from cardiac causes. At 12 months, there was no significant difference between patients receiving TITANOX-coated stent or PES in the rates of primary end point (10.3% vs. 12.8%, P=0.5), MI (4.2% vs. 8.1%, P=0.1), or TLR (9.3% vs. 7.1%, P=0.5), respectively. The incidence of stent thrombosis, defined according to Academic Research Consortium classification, was significantly lower in the TITANOX group compared to the PES group (0.9% vs. 4.3%, P=0.03). CONCLUSIONS: TITANOX-coated stent and PES resulted in comparable clinical outcomes during 12 months follow-up among patients treated for acute MI.
RCT Entities:
AIMS: The aim of this study was to evaluate the effectiveness of titanium-nitride-oxide (TITANOX)-coated stent and paclitaxel-eluting stent (PES) in patients presenting with acute myocardial infarction (MI). METHODS AND RESULTS: A total of 425 patients presenting with acute non-ST-elevation MI or ST-elevation MI were randomly assigned to receive TITANOX-coated stent or PES. The primary end point was a composite of MI, target lesion revascularisation (TLR) or death from cardiac causes. At 12 months, there was no significant difference between patients receiving TITANOX-coated stent or PES in the rates of primary end point (10.3% vs. 12.8%, P=0.5), MI (4.2% vs. 8.1%, P=0.1), or TLR (9.3% vs. 7.1%, P=0.5), respectively. The incidence of stent thrombosis, defined according to Academic Research Consortium classification, was significantly lower in the TITANOX group compared to the PES group (0.9% vs. 4.3%, P=0.03). CONCLUSIONS:TITANOX-coated stent and PES resulted in comparable clinical outcomes during 12 months follow-up among patients treated for acute MI.
Authors: Tuomas Lehtinen; K E Juhani Airaksinen; Antti Ylitalo; Pasi P Karjalainen Journal: Int J Cardiovasc Imaging Date: 2012-02-24 Impact factor: 2.357
Authors: Alban Dibra; Klaus Tiroch; Stefanie Schulz; Henning Kelbaek; Christian Spaulding; Gerrit J Laarman; Marco Valgimigli; Emilio Di Lorenzo; Christoph Kaiser; Ilkka Tierala; Julinda Mehilli; Gianluca Campo; Leif Thuesen; Maarten A Vink; Martin J Schalij; Roberto Violini; Albert Schömig; Adnan Kastrati Journal: Clin Res Cardiol Date: 2010-03-11 Impact factor: 5.460
Authors: Giuseppe De Luca; Marco Valgimigli; Christian Spaulding; Maurizio Menichelli; Hans Peter Brunner-La Rocca; Bas L van der Hoeven; Emilio Di Lorenzo; Luis-S Diaz de la Llera; Vincenzo Pasceri; Undine Pittl; Gianfranco Percoco; Roberto Violini; Gregg W Stone Journal: J Thromb Thrombolysis Date: 2009-02-04 Impact factor: 2.300